Guangdong Hybribio Biotech Co (SZSE:300639) Valuation Rank

View and export this data going back to 2017. Start your Free Trial

What is Guangdong Hybribio Biotech Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Guangdong Hybribio Biotech Co Valuation Rank Related Terms

Thank you for viewing the detailed overview of Guangdong Hybribio Biotech Co's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Guangdong Hybribio Biotech Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guangdong Hybribio Biotech Co Ltd (SZSE:300639) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

D 5-3-3-4, North High-tech Zone, Economic Development Zone, Chaozhou City, CHN, 521000

Website

http://www.hybribio.cn

Guangdong Hybribio Biotech Co Ltd is a Chinese company engaged in offering vitro diagnostic assays. Its products include in-vitro diagnostic kits, female sample collection kit, DNA extraction kit, and other devices. The company's products help in the infectious pathogens detection and genetic disease detection, including human papillomavirus, thalassemia, G6PD, hearing loss susceptibility, phenylketonuria, and early cancer detection, among others. The company has a business presence in China and various other countries.

Executives

Xie Long Xu	Directors, executives
Li Qing Hui	Executives
Wang Jian Yu	Directors, executives
Guan Zhi Sheng	Directors, executives
Qiu Mei Lan	Supervisors
Yuan Xian	Securities Affairs Representative
Tang You Gen	Independent director
Cai Dan Ping	Director
Chen Yi	Directors, executives
Xu Wan Jian	Supervisors
Huang Wei Xiong	Director
Guan Qiao Zhong	Directors, executives